Oncology Stocks
Biopharmaceutical and diagnostic entities in this sector focus on the research, development, and commercialization of precision therapies and screening tools designed to treat various forms of cancer. Revenue models transition from heavy R&D expenditure and clinical trial milestones to high-margin commercial sales or royalty streams upon regulatory approval.
As of Oct 23, 2026, Oncology has 336 US-listed companies worth $5.3T combined. The median member moved +1.7% over the past week; GMAB led among the 25 largest at +18.4% and MRNA trailed at -8.2%.
Companies in Oncology
- LLY – Eli Lilly and Company, $1.1T
- JNJ – Johnson & Johnson, $645B
- ABBV – AbbVie Inc, $505B
- MRK – Merck & Company Inc, $363B
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- AMGN – Amgen Inc, $237B
- GILD – Gilead Sciences Inc, $193B
- PFE – Pfizer Inc, $171B
- BMY – Bristol-Myers Squibb Company, $129B
- MCK – McKesson Corporation, $117B
- GSK – GlaxoSmithKline PLC ADR, $103B
- SNY – Sanofi ADR, $99.7B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- MRNA – Moderna Inc, $79.9B
- BSX – Boston Scientific Corp, $66.7B
- COR – Cencora Inc., $65B
- TAK – Takeda Pharmaceutical Co Ltd ADR, $64.7B
- NTRA – Natera Inc, $57.9B
- ONC – BeiGene, Ltd., $43B
- ILMN – Illumina Inc, $40.7B
- RVMD – Revolution Medicines Inc, $40.2B
- GMAB – Genmab AS, $26.9B
- DGX – Quest Diagnostics Incorporated, $26.9B
- UTHR – United Therapeutics Corporation, $25.1B
- INCY – Incyte Corporation, $23.7B
- BNTX – BioNTech SE, $22.9B
- GH – Guardant Health Inc, $21.9B
- MEDP – Medpace Holdings Inc, $18.3B
- EXEL – Exelixis Inc, $16.2B
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- BBIO – BridgeBio Pharma Inc, $13.4B
- SMMT – Summit Therapeutics PLC, $12.3B
- TEM – Tempus AI, Inc. Class A Common Stock, $12.3B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- RDY – Dr. Reddy’s Laboratories Ltd ADR, $11B
- CAI – Caris Life Sciences, Inc. Common Stock, $9B
- IBRX – Immunitybio Inc, $8.8B
- LNTH – Lantheus Holdings Inc, $6.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- GRAL – GRAIL, LLC, $5.7B
- COGT – Cogent Biosciences Inc, $5.5B
- MMSI – Merit Medical Systems Inc, $5.4B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- SRRK – Scholar Rock Holding Corp, $5.1B
- ERAS – Erasca Inc, $5.1B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- CRSP – Crispr Therapeutics AG, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- RLAY – Relay Therapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- VCYT – Veracyte Inc, $3.7B
- LEGN – Legend Biotech Corp, $3.7B
- IDYA – Ideaya Biosciences Inc, $3.5B
- CELC – Celcuity LLC, $3.2B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- ELVN – Enliven Therapeutics Inc., $2.9B
- NRIX – Nurix Therapeutics Inc, $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- ZLAB – Zai Lab Ltd, $2.7B
- HCM – HUTCHMED DRC, $2.5B
- MRVI – Maravai Lifesciences Holdings Inc, $2.4B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PGEN – Precigen Inc, $2.3B
- NEO – NeoGenomics Inc, $2.1B
- IMNM – Immunome Inc, $2.1B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- XNCR – Xencor Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- VIR – Vir Biotechnology Inc, $1.8B
- NVCR – Novocure Ltd, $1.8B
- NUVB – Nuvation Bio Inc, $1.7B
- PSNL – Personalis Inc, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- NBTX – Nanobiotix, $1.7B
- ANAB – AnaptysBio Inc, $1.5B
- IMCR – Immunocore Holdings Ltd, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- AAPG – Ascentage Pharma Group International, $1.4B
- FRNM – Freenome, Inc. Common stock, $1.4B
- DRTS – Alpha Tau Medical Ltd, $1.3B
- REPL – Replimune Group Inc, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- DMRA – Damora Therapeutics, Inc., $1.2B
- SNDX – Syndax Pharmaceuticals Inc, $1.2B
- JANX – Janux Therapeutics Inc, $1.1B
- CSTL – Castle Biosciences Inc, $1.1B
- IMTX – Immatics NV, $1B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- CGEM – Cullinan Oncology LLC, $961M
- KURA – Kura Oncology Inc, $944M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- RIGL – Rigel Pharmaceuticals Inc, $881M
- CRVS – Corvus Pharmaceuticals Inc, $876M
- SLBT – SL Science Holding Limited Ordinary Shares, $869M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SANA – Sana Biotechnology Inc, $835M
- AVBP – ArriVent BioPharma, Inc. Common Stock, $821M
- IMMX – Immix Biopharma Inc, $803M
- VSTM – Verastem Inc, $781M
- GERN – Geron Corporation, $771M
- CTKB – Cytek Biosciences Inc, $763M
- OBX – Obsidian Therapeutics, Inc. Common Stock, $741M
- FTH – Faeth Therapeutics, Inc., $733M
- NVCT – Nuvectis Pharma Inc, $716M
- CADL – Candel Therapeutics Inc, $709M
- SOPH – Sophia Genetics SA, $687M
- OLMA – Olema Pharmaceuticals Inc, $684M
- AURA – Aura Biosciences Inc, $678M
- STLN – The Oncology Institute, Inc., $655M
- FLGT – Fulgent Genetics Inc, $591M
- CTMX – CytomX Therapeutics Inc, $556M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- DCTH – Delcath Systems Inc, $534M
- CBIO – Crescent Biopharma, Inc., $532M
- PBYI – Puma Biotechnology Inc, $506M
- ALLO – Allogene Therapeutics Inc, $504M
- MNPR – Monopar Therapeutics Inc, $498M
- AUTL – Autolus Therapeutics Ltd, $482M
- YDES – YD Bio Ltd, $477M
- ANGO – AngioDynamics Inc, $473M
- ARVN – Arvinas Inc, $472M
- BLSM – BlossomHill Therapeutics, Inc. Common Stock, $458M
- EIKN – Eikon Therapeutics, Inc. Common Stock, $408M
- MYGN – Myriad Genetics Inc, $396M
- AUNA – Auna S.A., $394M
- INDP – Indaptus Therapeutics Inc, $380M
- FENC – Fennec Pharmaceuticals Inc, $358M
- RLMD – Relmada Therapeutics Inc, $347M
- AONC – American Oncology Network Inc., $336M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- CCCC – C4 Therapeutics Inc, $325M
- CYPH – Cypherpunk Technologies Inc., $299M
- BDSX – Biodesix Inc, $279M
- AGEN – Agenus Inc, $273M
- BBOT – BridgeBio Oncology Therapeutics, Inc., $265M
- INFU – InfuSystems Holdings Inc, $262M
- CATX – Perspective Therapeutics Inc., $259M
- PRLD – Prelude Therapeutics Inc, $258M
- IMRX – Immuneering Corp, $255M
- TLSI – TriSalus Life Sciences Inc., $250M
- IPSC – Century Therapeutics Inc, $250M
- BCYC – Bicycle Therapeutics Ltd, $245M
- PROF – Profound Medical Corp, $242M
- FATE – Fate Therapeutics Inc, $231M
- SLGL – Sol Gel Technologies Ltd, $227M
- GLSI – Greenwich Lifesciences Inc, $226M
- FOCL – EDAP TMS S.A., $222M
- PYXS – Pyxis Oncology Inc, $220M
- CGEN – Compugen, $219M
- MGNX – MacroGenics Inc, $218M
- ADCT – ADC Therapeutics SA, $217M
- LYEL – Lyell Immunopharma Inc, $213M
- ZNTL – Zentalis Pharmaceuticals Llc, $209M
- NNNN – Anbio Biotechnology Class A Ordinary Shares, $205M
- WHWK – Whitehawk Therapeutics, Inc., $194M
- STRO – Sutro Biopharma, $181M
- ALXO – Alx Oncology Holdings , $173M
- ADAG – Adagene Inc, $165M
- MOLN – Molecular Partners AG ADR, $165M
- QTRX – Quanterix Corp, $163M
- NKTX – Nkarta Inc, $161M
- IPHA – Innate Pharma, $160M
- NBP – NovaBridge Biosciences, $158M
- BNR – Burning Rock Biotech Ltd, $158M
- CHRS – Coherus BioSciences Inc, $156M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- CMPX – Compass Therapeutics Inc., $150M
- CNTN – Canton Strategic Holdings, Inc., $149M
- TARA – Protara Therapeutics Inc, $137M
- CLLS – Cellectis SA, $135M
- ENGN – enGene Holdings Inc. Common Stock, $119M
- CUE – Cue Biopharma, $117M
- HURA – TuHURA Biosciences Inc, $117M
- LUCD – Lucid Diagnostics Inc, $116M
- GNLX – Genelux Corporation Common Stock, $114M
- CPIX – Cumberland Pharmaceuticals Inc, $111M
- FHTX – Foghorn Therapeutics Inc, $110M
- BDTX – Black Diamond Therapeutics Inc, $105M
- PMVP – Pmv Pharmaceuticals Inc, $105M
- INO – Inovio Pharmaceuticals Inc, $102M
- ANIX – Anixa Biosciences Inc, $101M
- OKUR – OnKure Therapeutics, Inc., $97.6M
- ATRA – Atara Biotherapeutics Inc, $96M
- KZIA – Kazia Therapeutics Ltd ADR, $89.7M
- CRBP – Corbus Pharmaceuticals Holding, $85.5M
- ACRV – Acrivon Therapeutics, Inc. Common Stock, $81.8M
- CTOR – Citius Oncology, Inc., $81.2M
- TELO – Telomir Pharmaceuticals, Inc. Common Stock, $80.2M
- NTHI – NeOnc Technologies Holdings, Inc. Common Stock, $79.2M
- OSTX – OS Therapies Incorporated, $75.8M
- RFL – Rafael Holdings, Inc., $74.4M
- ONCY – Oncolytics Biotech Inc, $71.8M
- MAIA – MAIA Biotechnology Inc., $71.6M
- CRDF – Cardiff Oncology Inc, $70.1M
- APLM – Apollomics Inc. Class A Ordinary Shares, $67.8M
- FBIO – Fortress Biotech Inc, $67.7M
Showing the 200 largest of 336 members by market cap.